The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I trial of intraperitoneal (IP) mesothelin (MSLN)-targeted CAR T-cell therapy in patients with MSLN-positive esophagogastric cancer (EGC) with peritoneal carcinomatosis.
 
Joan Choo
No Relationships to Disclose
 
Jasmeen Saini
No Relationships to Disclose
 
Adrian Gonzalez - Aguirre
No Relationships to Disclose
 
Parastoo Dahi
Consulting or Advisory Role - Kite, a Gilead company
 
Sophie Hieronymi
No Relationships to Disclose
 
Stacy Fernstedt
No Relationships to Disclose
 
Kay Tan
No Relationships to Disclose
 
Prasad Adusumilli
Consulting or Advisory Role - Atara Biotherapeutics; Bayer; BioArdis; Carisma Therapeutics; ImmPACT-Bio; Imugene; Orion; Outpace Bio
Research Funding - Atara Biotherapeutics
Patents, Royalties, Other Intellectual Property - Atara Biotherapeutics
 
Geoffrey Ku
Consulting or Advisory Role - Apexigen; AstraZeneca/Daiichi Sankyo; Bristol-Myers Squibb; I-Mab; Jazz Pharmaceuticals; Merck Sharp & Dohme; Pieris Pharmaceuticals
Research Funding - Adaptimmune (Inst); Arog (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); CARsgen Therapeutics (Inst); Daiichi Sankyo (Inst); Jazz Pharmaceuticals (Inst); Merck (Inst); Oncolys BioPharma (Inst); Pieris Pharmaceuticals (Inst); Triumvira Immunologics, Inc (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Aduro Biotech; AstraZeneca/MedImmune; Bristol-Myers Squibb; ImaBiotech; Merck Sharp & Dohme; Pieris Pharmaceuticals